Dana Farber Cancer Institute

We track 2 ClinicalTrials.gov studies led by Dana Farber Cancer Institute. The portfolio skews toward Phase 2 (2 trials).

2 clinical trials sponsored by Dana Farber Cancer Institute.

Pipeline by Phase

PhaseTrialsDistribution
Phase 2 2
100%

Trial Status Breakdown

Trials by Dana Farber Cancer Institute

20-347 NCT Number Title A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

NCT04569747 · ACTIVE NOT RECRUITING · Phase 2

A Phase II Study of Osimertinib With On-study and Post-progression Biopsy in the First Line Treatment of EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

NCT03586453 · RECRUITING · Phase 2

Frequently Asked Questions

How many clinical trials does Dana Farber Cancer Institute sponsor?

Dana Farber Cancer Institute currently sponsors 2 clinical trials tracked on ReadTheTrial. These span Phase 2.

What conditions does Dana Farber Cancer Institute research?

Dana Farber Cancer Institute conducts research across multiple therapeutic areas. Browse the trial listings for details.

Is Dana Farber Cancer Institute recruiting for clinical trials?

Yes, Dana Farber Cancer Institute currently has 1 trial that are actively recruiting participants. Check individual trial pages for eligibility criteria and locations.

Explore More